Click here to close
Hello! We notice that you are using Internet Explorer, which is not supported by Xenbase and may cause the site to display incorrectly.
We suggest using a current version of Chrome,
FireFox, or Safari.
Neurochem Res
1999 Oct 01;2410:1233-40. doi: 10.1023/a:1020968922151.
Show Gene links
Show Anatomy links
In-vitro and in-vivo action of cannabinoids.
Akinshola BE
,
Chakrabarti A
,
Onaivi ES
.
???displayArticle.abstract???
The discovery of endocannabinoids such as anandamide and the wide spread localization of cannabinoid receptors in the brain and peripheral tissues, suggests that the cannabinoid system represents a previously unrecognized ubiquitous net work in the nervous system, whose physiology and function is unfolding. In this study, we tested the hypothesis that some of the actions of anandamide are independent of a cannabinoid receptor mechanism. This was accomplished by the use of cannabinoid agonist and antagonist interaction in an in-vitro and in-vivo test systems. In-vitro, we used Xenopus laevis oocytes expression system and two-voltage clamp technique in combination with differential display polymerase chain reaction to determine whether the differential display of genes following treatment with anandamide may be linked to AMPA glutamate receptor. The differential expression of genes in vivo after the sub-acute administration of anandamide could not be directly linked with the AMPA glutamate receptor. In the voltage clamp studies we investigated the effects of anandamide on recombinant AMPA GluR3 subunit currents generated by kainic acid in oocytes expressing the AMPA glutamate receptor. In the in-vitro studies, we present evidence that anandamide inhibited the kainate activated currents in oocytes expressing AMPA glutamate receptor involves cAMP transduction via a cannabinoid receptor independent mechanism. In the in-vivo studies, SR141716A, the CB1 antagonist, induced anxiolysis, that was dependent on the mouse strain used in the anxiety model and blocked the anxiogenic effects of anandamide or methanandamide whereas SR141716A had no effect on the anandamide inhibition of kainate activated currents in-vitro.
???displayArticle.pubmedLink???
10492518
???displayArticle.link???Neurochem Res ???displayArticle.grants???[+]
Axelrod,
Cannabinoid receptors and their endogenous agonist, anandamide.
1998, Pubmed
Axelrod,
Cannabinoid receptors and their endogenous agonist, anandamide.
1998,
Pubmed
Bliss,
A synaptic model of memory: long-term potentiation in the hippocampus.
1993,
Pubmed
Burstein,
Prostaglandins and cannabis--VI. Release of arachidonic acid from HeLa cells by delta1-tetrahydrocannabinol and other cannabinoids.
1978,
Pubmed
Chakrabarti,
Neurobehavioral effects of anandamide and cannabinoid receptor gene expression in mice.
1998,
Pubmed
DeLean,
Simultaneous analysis of families of sigmoidal curves: application to bioassay, radioligand assay, and physiological dose-response curves.
1978,
Pubmed
Devane,
Isolation and structure of a brain constituent that binds to the cannabinoid receptor.
1992,
Pubmed
Di Marzo,
Formation and inactivation of endogenous cannabinoid anandamide in central neurons.
1994,
Pubmed
Felder,
Isolation and measurement of the endogenous cannabinoid receptor agonist, anandamide, in brain and peripheral tissues of human and rat.
1996,
Pubmed
Hampson,
Dual effects of anandamide on NMDA receptor-mediated responses and neurotransmission.
1998,
Pubmed
,
Xenbase
Keller,
Calcium influx through subunits GluR1/GluR3 of kainate/AMPA receptor channels is regulated by cAMP dependent protein kinase.
1992,
Pubmed
,
Xenbase
Lake,
Cardiovascular effects of anandamide in anesthetized and conscious normotensive and hypertensive rats.
1997,
Pubmed
Mailleux,
Glutamatergic regulation of cannabinoid receptor gene expression in the caudate-putamen.
1994,
Pubmed
Matsuda,
Molecular aspects of cannabinoid receptors.
1997,
Pubmed
Onaivi,
Cannabinoid receptor genes.
1996,
Pubmed
Onaivi,
Pharmacological characterization of cannabinoids in the elevated plus maze.
1990,
Pubmed
Onaivi,
Neuropharmacological and physiological validation of a computer-controlled two-compartment black and white box for the assessment of anxiety.
1989,
Pubmed
Pertwee,
Pharmacology of cannabinoid CB1 and CB2 receptors.
1997,
Pubmed
Reichman,
Delta 9-tetrahydrocannabinol inhibits arachidonic acid acylation of phospholipids and triacylglycerols in guinea pig cerebral cortex slices.
1991,
Pubmed
Reichman,
Delta 9-tetrahydrocannabinol increases arachidonic acid levels in guinea pig cerebral cortex slices.
1988,
Pubmed
Rhee,
Cannabinoid receptor activation differentially regulates the various adenylyl cyclase isozymes.
1998,
Pubmed
Tabuchi,
Lipid mediators modulate NMDA receptor currents in a Xenopus oocyte expression system.
1997,
Pubmed
,
Xenbase
Valenzuela,
Alcohol and neurotransmitter interactions.
1997,
Pubmed
Venance,
Inhibition by anandamide of gap junctions and intercellular calcium signalling in striatal astrocytes.
1995,
Pubmed
